New considerations in monitoring for hydroxychloroquine retinopathy

Clinical Eye and Vision Care

Volumn 8, Issue 2, 1996, Pages 99-104

  Tokumaru, Gay K ^a  

^a Hampton VA Medical Center   (United States)

Author keywords

Hydroxychloroquine maculopathy; Hydroxychloroquine retinopathy; Plaquenil

Indexed keywords

HYDROXYCHLOROQUINE; HYDROXYCHLOROQUINE SULFATE;

ARTICLE; AUTOIMMUNITY; DRUG THERAPY; FOLLOW UP; HUMAN; KIDNEY DISEASE; PATIENT MONITORING; PRACTICE GUIDELINE; RETINOPATHY; RHEUMATOID ARTHRITIS; RISK; SELF EVALUATION; SYSTEMIC LUPUS ERYTHEMATOSUS; VISUAL ACUITY; VISUAL FIELD;

EID: 0029890334     PISSN: 09534431     EISSN: None     Source Type: Journal    
DOI: 10.1016/0953-4431(96)00162-2     Document Type: Article

References (26)

1. The HERA Study Group. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA study. Am J Med 1995; 98:156-168.
2. Aylward JM. Hydroxychloroquine and chloroquine: assessing the risk of retinal toxicity. J Am Optom Assoc 1993; 64:787-797.
3. Mackenzie AH. Antimalarial drugs for rheumatoid arthritis. Am J Med 1983; 75(suppl):48-58.
4. Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 1983; 75(Suppl IA):40-45.
5. Johnson MW, Vine AK. Hydroxychloroquine therapy in massive total doses without retinal toxicity. Am J Ophthalmol 1987; 104:139-144.
6. Morsman CDG, Livesey SJ, Richards IM, Jessop JD, Mills PV. Screening for hydroxychloroquine retinal toxicity: is it necessary? Eye 1990; 4:572-576.
7. Bernstein HN. Ocular safety of hydroxychloroquine. Ann Ophthalmol 1991; 23:292-296.
8. Spalton DJ, Roe GMJ, Hughes, GRV. Hydroxychloroquine, dosage parameters and retinopathy. Lupus 1993; 2:355-358.
9. Potter B. Hydroxychloroquine. Cutis 1993; 52:229-231.
10. Easterbrook M. The ocular safety of hydroxychloroquine. Sem Arthritis Rheum 1993; 23(2)Suppl:62-67.
11. Bernstein HN. Ocular safety of hydroxychloroquine sulfate (Plaquenil). Southern Med J 1992; 85(3):274-279.
12. Weiner A, Sandberg MA, Gaudio AR, Kini MM, Berson EL. Hydroxychloroquine retinopathy. Am J Ophthalmol 1991; 112:528-534.
13. Falcone PM, Paolini L, Lou PL. Hydroxychloroquine toxicity despite normal dose therapy. Ann Ophthalmol 1993; 25:385-388.
14. Shearer RV, Dubois EL. Ocular changes induced by long-term hydroxychloroquine (Plaquenil) therapy. Am J Ophthalmol 1967; 64(2):245-252.
15. Easterbrook M. Long-term course of antimalarial maculopathy after cessation of treatment. Can J Ophthalmol 1992; 27(5):237-239.
16. AHFS Drug Information 95. American Society of Health-System Pharmacists, Bethesda, 1995.
17. Easterbrook M. Editorial: screening for antimalarial toxicity. Can J Ophthalmol 1993; 28(2):51-52.
18. Cox NM, Paterson WD. Ocular toxicity of antimalarials in dermatology: a survey of current practice. Br J Dermatol 1994; 131:878-882.
19. Mazzuca SA, Yung R, Brandt KD, Yee RD, Katz BP. Current practices for monitoring ocular toxicity related to hydroxychloroquine (Plaquenil) therapy. J Rheum 1994; 21(1):59-63.
20. Hart WM JF, Burde RM, Johnston GP et al. Static perimetry in chloroquine retinopathy: perifoveal patterns of visual field depression. Arch Ophthalmol 1984; 102:377-380.
21. Rynes RI. Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment. Am J Med 1983; 75 (suppl):35-39.
22. Tobin DR, Krobel GB, Rynes RI. Hydroxychloroquine: seven-year experience. Arch Ophthalmol 1982; 100:81-83.
23. Spalton DJ. Chloroquine and the eye. Br J Clin Pract 1987; (supp)52:50-55.
24. Ruiz RS, Saatci OA. Chloroquine and hydroxychloroquine retinopathy: how to follow affected patients. Ann Ophthalmol 1991; 23:290-291.
25. College of Ophthalmologists. Chloroquine, Hydroxychloroquine and the Eye, 1993.
26. National Systemic Disease Committee, American Optometric Association. Plaquenil and the Eye, 1994.